Pediatric Cryptorchidism Surgery 

  • Author: Marcos Perez-Brayfield, MD; Chief Editor: Marc Cendron, MD   more...
 
Updated: Nov 10, 2011
 

Background

Cryptorchidism is the most common abnormality of male sexual development. In this condition, the testis is not located in the scrotum. The testis can be ectopic, incompletely descended, retractile, and absent or atrophic. The term cryptorchidism is translated from a Greek term that means hidden or obscure testis. Sir John Hunter, the British anatomist, reported this condition in 1786. In 1877, Annandale performed the first successful orchidopexy. In 1899, Bevan published the principles of testicular mobilization, separation of the processus vaginalis, and repositioning of the testis into the scrotum. Testicular maldescent has been the subject of many clinical studies, but its embryology, effects on fertility, and ultimate clinical impact still remain a topic of discussion and research.

Next

Pathophysiology

Embryology of testis development

The embryology of testis development is critical to understanding the most common theories that explain cryptorchidism.

Shortly after 6 weeks' gestation, the testis-determining SRY gene on chromosome Y directly affects the differentiation of the indifferent gonad into a testis. Germ cells are located in the germinal ridge close to the kidney in the retroperitoneum. Around 6-7 weeks' gestation, Sertoli cells develop and secrete Müllerian inhibitory substance (MIS), which leads to the regression of the female genital organs. Around 9 weeks' gestation, Leydig cells start producing testosterone, which promotes development of the wolffian duct into portions of the male genital tract. Concurrently, the testis organizes as a distinct organ with its distinct seminiferous tubules surrounded by vessels and encapsulated by the tunica albuginea. Owing to the differential growth of the fetus, the testicles move into the pelvis, close to the internal ring.

The testis remains in a retroperitoneal position until 28 weeks' gestation, at which time inguinal descent of the testicle begins. Most testes have completed their descent into the scrotum by 40 weeks' gestation.

Theories of cryptorchidism pathophysiology

Several theories have been offered to explain the pathophysiology of cryptorchidism, including gubernacular abnormalities, reduced intra-abdominal pressures, intrinsic testicular and/or epididymal abnormalities, and endocrine abnormalities, as well as anatomic anomalies (eg, fibrous bands within the inguinal canal or abnormal arrangement of the cremasteric muscle fibers).

The gubernaculum testis is a structure that attaches the lower portion of the tunica vaginalis to base of the scrotum. The gubernaculum is thought to aid in testicular descent by widening the inguinal canal and guiding the testis down to the scrotum. Therefore, anomalies in this attachment may contribute to cryptorchidism.

Cryptorchidism is common in patients with prune belly syndrome and those with gastroschisis; both are associated with decreased intra-abdominal pressures. However, the theory based on reduced pressures does not explain most cases of cryptorchidism.

Another theory of testicular maldescent is based on intrinsic testicular and/or epididymal abnormalities. Several studies have shown that, histologically, the germinal epithelium of the maldescended testis may be abnormal. Infertility is associated with cryptorchidism, and the risk of infertility increases with the degree of maldescent. Moreover, approximately 23%-86% of maldescended testes have been associated with some form of epididymal abnormality. Studies have shown an increase in the degree of epididymal abnormalities in intra-abdominal testis compared with mild cases of cryptorchidism.[1]

Abnormalities in the hypothalamic-pituitary-gonadal axis have been postulated as a possible explanation for anomalies of testicular descent and abnormal germ-cell development. However, both animal and human endocrine studies have not been able to shed clear light on the pathophysiology of testicular maldescent. The causative hormonal abnormality may be found at different levels. The fact that the condition most often affects one side indicates that endocrine anomalies may be partially responsible but does not completely explain why the testis does not descend normally.

Current and future research

The molecular mechanisms by which the newly determined testicle descends from its position in the posterior abdomen into the scrotum is a complex process that likely involves multiple genetic, hormonal, environmental, and stochastic factors. Although a comprehensive explanation has not yet been elucidated, several exciting observations suggest that specific genetic loci play important roles in normal testicular descent and the occurrence of cryptorchidism.

Models for the study of cryptorchidism include experiments in knockout mice. Homozygous mutants for the loss of Hoxa-10 and Hoxa-11 exhibit cryptorchidism. Both genes are members of the family of homeobox (Hox) genes, which are highly conserved throughout evolution and which play a critical role in anteroposterior positioning in the developing embryo. Early orchiopexy rescues Hoxa-11 mutants from an infertile state. Hoxa-10 polymorphisms have been found in human cryptorchid populations, although the functional significance of these genetic changes has not yet been established.

In the literature, much attention has been focused on insulinlike factor 3 (Insl-3 or relaxinlike factor) and its receptor, leucine-rich repeat-containing G protein-coupled receptor 8 (LGR8), or G-protein–coupled receptor affecting testes descent (GREAT).[2] Homozygous knockouts of either Insl-3 or LGR8 lead to the phenotype of bilateral intra-abdominal testes. As in the murine Hoxa-11 model, early orchiopexy of Insl-3–genetically deficient mice allows for the development of fertility.

Although some have suggested that mutations in the Insl-3 gene might not play a substantial role in human cryptorchidism, a missense mutation in Insl-3 has been found in a patient with cryptorchidism; this mutation causes a nonconservative amino acid substitution. A proof-of-principle study has not yet been conducted to determine if this Insl-3 mutation leads to cryptorchidism.

LGR8 polymorphisms have been identified in both cryptorchid and healthy human populations. One of the receptor mutations found in a cryptorchid patient precluded a response to ligand stimulation in vitro.

In the search for a genetic cause of cryptorchidism, other areas of focus include Y-chromosome microdeletions, increased aromatase activity, and abnormalities in the Wilms tumor gene (WT1).

Previous
Next

Epidemiology

Frequency

United States

A palpable undescended testis is found in 3%-5% of newborns, and bilateral undescended testis is found in 15% of newborns with cryptorchidism. Most undescended palpable testes later spontaneously descend within the first 4 months of life; only 0.7%-1% of 1-year-old infants have a persistent undescended testis. Studies have shown that spontaneous descent does not occur after age 9 months. The incidence does not change between age 1 year and adulthood. However, some testes that were descended in early childhood may ascend later in life.

Nonpalpable testes account for approximately 20% of all undescended testes. Approximately 40% of the nonpalpable testes are intra-abdominal, 40% are inguinal, and 20% are atrophic or absent.

Cryptorchidism is found in 30% of babies born prematurely. Other predisposing factors include low birth weight, small size for gestational age, twin pregnancy, and maternal estrogen exposure. Cryptorchidism is found in 7% of siblings and in about 2% of fathers of babies with this condition.

Mortality/Morbidity

Cryptorchidism has not been associated with any factors for mortality. However, testicular maldescent has been associated with a slight increase in the risk of testicular cancer, infertility, trauma, and testicular torsion. If not treated, testicular maldescent may also affect the psychological well-being of young men in whom negative self-esteem issues may arise.

Race

Cryptorchidism has no reported racial predilection.

Sex

Cryptorchidism affects only males.

Age

See Frequency above.

Previous
 
 
Contributor Information and Disclosures
Author

Marcos Perez-Brayfield, MD  Consulting Staff, HIMA-San Pablo; Assistant Professor, University of Puerto Rico School of Medicine

Marcos Perez-Brayfield, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, and American Urological Association

Disclosure: Nothing to disclose.

Coauthor(s)

Andrew J Kirsch, MD, FAAP, FACS  Clinical Professor of Urology, Emory University School of Medicine, Children's Healthcare of Atlanta; President, Georgia Urology, PA

Andrew J Kirsch, MD, FAAP, FACS is a member of the following medical societies: American Academy of Pediatrics, American Urological Association, and Society for Fetal Urology

Disclosure: QMED Grant/research funds Investigation, Consulting; COOK Urological Royalty Consulting

Adam G Baseman, MD  Pediatric Urologist, North Texas Pediatric Urology Associates, Urology Clinics of North Texas

Disclosure: Nothing to disclose.

Specialty Editor Board

Bartley G Cilento, Jr, MD  Instructor, Department of Surgery, Division of Urology, Children's Hospital of Boston and Harvard Medical School

Bartley G Cilento, Jr, MD is a member of the following medical societies: American Academy of Pediatrics, American Urological Association, and Massachusetts Medical Society

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Harry P Koo, MD  Chairman of Urology Division and Director of Pediatric Urology, Professor of Surgery, Virginia Commonwealth University School of Medicine, Medical College of Virginia; Director of Urology, Children's Hospital of Richmond

Harry P Koo, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Surgeons, and American Urological Association

Disclosure: Nothing to disclose.

Paul D Petry, DO, FACOP, FAAP  Consulting Staff, Freeman Pediatric Care, Freeman Health System

Paul D Petry, DO, FACOP, FAAP is a member of the following medical societies: American Academy of Osteopathy, American Academy of Pediatrics, American College of Osteopathic Pediatricians, and American Osteopathic Association

Disclosure: Nothing to disclose.

Chief Editor

Marc Cendron, MD  Associate Professor of Surgery, Harvard School of Medicine; Consulting Staff, Department of Urological Surgery, Children's Hospital Boston

Marc Cendron, MD is a member of the following medical societies: American Academy of Pediatrics, American Urological Association, European Society for Paediatric Urology, Johns Hopkins Medical and Surgical Association, New Hampshire Medical Society, Society for Fetal Urology, and Society for Pediatric Urology

Disclosure: Nothing to disclose.

References
  1. Barthold JS, Redman JF. Association of epididymal anomalies with patent processus vaginalis in hernia, hydrocele and cryptorchidism. J Urol. Dec 1996;156(6):2054-6. [Medline].

  2. Nguyen MT, Showalter PR, Timmons CF, Nef S, Parada LF, Baker LA. Effects of orchiopexy on congenitally cryptorchid insulin-3 knockout mice. J Urol. Oct 2002;168(4 Pt 2):1779-83; discussion 1783. [Medline].

  3. Tasian GE, Copp HL, Baskin LS. Diagnostic imaging in cryptorchidism: utility, indications, and effectiveness. J Pediatr Surg. Dec 2011;46(12):2406-13. [Medline].

  4. Cuda SP, Srinivasan AK, Kalisvaart J, Kirsch AJ. Evolution of single practice trends in the surgical approach to the undescended testicle. J Urol. Jun 2011;185(6 Suppl):2451-4. [Medline].

  5. Sfoungaris D, Mouravas V, Petropoulos A, Filippopoulos A. Prentiss orchiopexy applied in younger age group. J Pediatr Urol. Nov 1 2011;[Medline].

  6. Kim SO, Hwang EC, Hwang IS, et al. Testicular Catch up Growth: The Impact of Orchiopexy Age. Urology. Oct 2011;78(4):886-9. [Medline].

  7. Banieghbal B, Davies M. Laparoscopic evaluation of testicular mobility as a guide to management of intra-abdominal testes. World J Urol. May 2003;20(6):343-5. [Medline].

  8. Bassel YS, Scherz HC, Kirsch AJ. Scrotal incision orchiopexy for undescended testes with or without a patent processus vaginalis. J Urol. Apr 2007;177(4):1516-8. [Medline].

  9. Breyer BN, DiSandro M, Baskin LS, Hsieh MH. Obesity does not decrease the accuracy of testicular examination in anesthetized boys with cryptorchidism. J Urol. Feb 2009;181(2):830-4. [Medline].

  10. Ferlin A, Simonato M, Bartoloni L, et al. The INSL3-LGR8/GREAT ligand-receptor pair in human cryptorchidism. J Clin Endocrinol Metab. Sep 2003;88(9):4273-9. [Medline].

  11. Giannopoulos MF, Vlachakis IG, Charissis GC. 13 Years' experience with the combined hormonal therapy of cryptorchidism. Horm Res. 2001;55(1):33-7. [Medline].

  12. Hack WW, van der Voort-Doedens LM, Sijstermans K, Meijer RW, Pierik FH. Reduction in the number of orchidopexies for cryptorchidism after recognition of acquired undescended testis and implementation of expectative policy. Acta Paediatr. Jun 2007;96(6):915-8. [Medline].

  13. Hutson JM, Hasthorpe S, Heyns CF. Anatomical and functional aspects of testicular descent and cryptorchidism. Endocr Rev. Apr 1997;18(2):259-80. [Medline].

  14. Kaleva M, Arsalo A, Louhimo I, et al. Treatment with human chorionic gonadotrophin for cryptorchidism: clinical and histological effects. Int J Androl. Oct 1996;19(5):293-8. [Medline].

  15. Koff SA, Sethi PS. Treatment of high undescended testes by low spermatic vessel ligation: an alternative to the Fowler-Stephens technique. J Urol. Aug 1996;156(2 Pt 2):799-803; discussion 803. [Medline].

  16. Law GS, Perez LM, Joseph DB. Two-stage Fowler-Stephens orchiopexy with laparoscopic clipping of the spermatic vessels. J Urol. Sep 1997;158(3 Pt 2):1205-7. [Medline].

  17. Lee MM, Donahoe PK, Silverman BL, et al. Measurements of serum müllerian inhibiting substance in the evaluation of children with nonpalpable gonads. N Engl J Med. May 22 1997;336(21):1480-6. [Medline].

  18. Lee PA, Coughlin MT. Fertility after bilateral cryptorchidism. Evaluation by paternity, hormone, and semen data. Horm Res. 2001;55(1):28-32. [Medline].

  19. Lee PA, Coughlin MT. The single testis: paternity after presentation as unilateral cryptorchidism. J Urol. Oct 2002;168(4 Pt 2):1680-2; discussion 1682-3. [Medline].

  20. Lee PA, O'Leary LA, Songer NJ, et al. Paternity after bilateral cryptorchidism. A controlled study. Arch Pediatr Adolesc Med. Mar 1997;151(3):260-3. [Medline].

  21. Lenzi A, Gandini L, Lombardo F, et al. Unilateral cryptorchidism corrected in prepubertal age: evaluation of sperm parameters, hormones, and antisperm antibodies in adult age. Fertil Steril. May 1997;67(5):943-8. [Medline].

  22. Lewis AG, Pecha BR, Smith EP, et al. Early orchiopexy restores fertility in the Hoxa 11 gene knockout mouse. J Urol. Jul 2003;170(1):302-5. [Medline].

  23. Lim HN, Hughes IA, Hawkins JR. Clinical and molecular evidence for the role of androgens and WT1 in testis descent. Mol Cell Endocrinol. Dec 20 2001;185(1-2):43-50. [Medline].

  24. Lindgren BW, Darby EC, Faiella L, et al. Laparoscopic orchiopexy: procedure of choice for the nonpalpable testis?. J Urol. Jun 1998;159(6):2132-5. [Medline].

  25. Matthews LA, Abdul-Karim FW, Elder JS. Effect of preoperative human chorionic gonadotropin on intra-abdominal rat testes undergoing standard and Fowler-Stephens orchiopexy. J Urol. Jun 1997;157(6):2315-7. [Medline].

  26. Merry C, Sweeney B, Puri P. The vanishing testis: anatomical and histological findings. Eur Urol. 1997;31(1):65-7. [Medline].

  27. Miller KD, Coughlin MT, Lee PA. Fertility after unilateral cryptorchidism. Paternity, time to conception, pretreatment testicular location and size, hormone and sperm parameters. Horm Res. 2001;55(5):249-53. [Medline].

  28. Mirilas P, Mamoulakis C, De Almeida M. Puberty does not induce serum antisperm surface antibodies in patients with previously operated cryptorchidism. J Urol. Dec 2003;170(6 Pt 1):2432-5. [Medline].

  29. Nane I, Ziylan O, Esen T, Kocak T, Ander H, Tellaloglu S. Primary gonadotropin releasing hormone and adjunctive human chorionic gonadotropin treatment in cryptorchidism: a clinical trial. Urology. Jan 1997;49(1):108-11. [Medline].

  30. Palmer LS, Gill B, Kogan SJ. Endocrine analysis of childhood monorchism. J Urol. Aug 1997;158(2):594-6. [Medline].

  31. Pettersson A, Richiardi L, Nordenskjold A, Kaijser M, Akre O. Age at surgery for undescended testis and risk of testicular cancer. N Engl J Med. May 3 2007;356(18):1835-41. [Medline].

  32. Pohl HG, Joyce GF, Wise M, Cilento BG Jr. Cryptorchidism and hypospadias. J Urol. May 2007;177(5):1646-51. [Medline].

  33. Radmayr C, Oswald J, Schwentner C, Neururer R, Peschel R, Bartsch G. Long-term outcome of laparoscopically managed nonpalpable testes. J Urol. Dec 2003;170(6 Pt 1):2409-11. [Medline].

  34. Thorsson AV, Christiansen P, Ritzen M. Efficacy and safety of hormonal treatment of cryptorchidism: current state of the art. Acta Paediatr. May 2007;96(5):628-30. [Medline].

  35. Toppari J. Physiology and disorders of testicular descent. Endocr Dev. 2003;5:104-9. [Medline].

  36. Wood HM, Elder JS. Cryptorchidism and testicular cancer: separating fact from fiction. J Urol. Feb 2009;181(2):452-61. [Medline].

Previous
Next
 
Hypoplastic right hemiscrotum in a patient with an undescended right testis.
Ectopic testis.
Diagnostic laparoscopy of a crossed ectopic testis.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.